Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK2 | Q9NYY3 | 12/20 | 0.35 |
| ▸ | PLK1 | P53350 | 10/20 | 0.35 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.33 |
| ▸ | CD38 | P28907 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2344507 | 1.00 | PLK2 (0.35) | PLK2PLK1PLK3CD38SIGMAR1 | |
| SCHEMBL2053287 | 0.97 | PLK2 (0.35) | PLK2PLK1PLK3CD38SIGMAR1 | |
| SCHEMBL6844666 | 0.97 | PLK2 (0.35) | PLK2PLK1PLK3CD38SIGMAR1 | |
| SCHEMBL2053288 | 0.97 | PLK2 (0.35) | PLK2PLK1PLK3CD38SIGMAR1 | |
| SCHEMBL2342072 | 0.89 | PLK2 (0.35) | PLK2PLK1CD38NOS2 | |
| SCHEMBL2049947 | 0.82 | PLK2 (0.33) | PLK2PLK1PLK3CD38 | |
| SCHEMBL2049945 | 0.82 | PLK2 (0.33) | PLK2PLK1PLK3CD38 | |
| SCHEMBL2689396 | 0.80 | SIGMAR1 (0.32) | SIGMAR1 | |
| SCHEMBL2048583 | 0.80 | PLK2 (0.51) | PLK2PLK1PLK3 | |
| SCHEMBL2048588 | 0.80 | PLK2 (0.51) | PLK2PLK1PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516441-B1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-20130331376-A1 | INHIBITORS OF POLO-LIKE KINASE | Elan Corporation, Inc. (US) | 2013-12-12 | — | — | US | disclosed |
| US-8541418-B2 | Inhibitors of polo-like kinase | ELAN PHARMACEUTICAL, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331376-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | PLK2 22/4885PLK1 1/4885PLK3 101/4885 |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | PLK2 22/4885PLK1 1/4885PLK3 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.